Status:
ACTIVE_NOT_RECRUITING
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Metastatic Uveal Melanoma
Eligibility:
All Genders
18-100 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a sin...
Detailed Description
This is a First in Human (FIH), phase I/II, open label, multi-center study of DYP688 as a single agent. There will be two parts to this study: a phase I, dose escalation part followed by a phase II pa...
Eligibility Criteria
Inclusion
- Patients in the dose escalation part must be ≥ 18 years of age at the time of informed consent (ICF) signature. In the phase II part, patients ≥ 12 years of age at the time of informed consent may be eligible for enrollment (not applicable in countries where enrollment is restricted by the local health authority to patients ≥ 18 years of age). Patients must have a minimum weight of 40 kg.
- ECOG performance status ≤ 1 for patients ≥ 18 years of age; Karnofsky performance status ≥ 70 for patients ≥ 16 and \< 18 years of age; Lansky performance status ≥ 70 for patients ≥ 12 and \< 16 years of age
- Patients must be suitable and willing to undergo study required biopsies according to the treating institution's own guidelines and requirements. If a biopsy is not medically feasible, exceptions may be considered after documented discussion with Novartis.
- For all patients in Dose Escalation
- MUM: uveal melanoma with histologically or cytologically confirmed metastatic disease. Patient must be either treatment naive or have received any number of prior lines and progressed on most recent therapy
- Non-MUM: advanced cutaneous or mucosal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies and has evidence of GNAQ/11 mutation based on local data
- For patients in Phase II
- Tebentafusp naïve group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following standard therapies or that has no satisfactory alternative therapies
- Tebentafusp pre-treated group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease. Patients must be previously treated with tebentafusp and have progressed
- Non-MUM: patients with diagnosis of cutaneous or mucosal melanomas harboring GNAQ/11 mutations based on local data, with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies
Exclusion
- Malignant disease, other than that being treated in this study.
- Active brain metastases, i.e. symptomatic brain metastases or known leptomeningeal disease.
- Evidence of active bleeding or bleeding diathesis or significant coagulopathy (including familial) or a medical condition requiring long term systemic anticoagulation that would interfere with biopsies.
- History of anaphylactic or other severe hypersensitivity / infusion reactions to ADCs or monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
- Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:
- 2 weeks for fluoropyrimidine therapy
- 4 weeks for radiation therapy or limited field radiation for palliation within ≤ 2 weeks prior to the first dose of study treatment.
- 4 weeks or ≤ 5 half-lives (whichever is shorter) for chemotherapy or biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other investigational agent.
- 6 weeks for cytotoxic agents with major delayed toxicities, such as nitrosoureas and mitomycin C.
- 4 weeks for immuno-oncologic therapy, such as CTLA-4, PD-1, or PD-L1 antagonists.
- Clinically significant and / or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA grade ≥ 2) or clinically significant arrhythmia despite medical treatment.
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
July 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2027
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT05415072
Start Date
July 4 2022
End Date
October 1 2027
Last Update
July 20 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital Hematology Oncology
Boston, Massachusetts, United States, 02114
2
Columbia University Medical Center- New York Presbyterian Onc Dept
New York, New York, United States, 10032
3
Memorial Sloane Kettering Cancer Center MSKCC
New York, New York, United States, 10065
4
Novartis Investigative Site
Westmead, New South Wales, Australia, 2145